ALLEGAN, Mich., March 1, 2011 /PRNewswire/ — Perrigo (Nasdaq:
PRGO;TASE) today announced that, as part of the anticipated
follow-up to the warning letter Perrigo received on April 30, 2010,
the Detroit Office of the Food and Drug Administration (FDA) has
arrived at their Allegan facility for the re-inspection.
Perrigo Company is a leading global healthcare supplier that
develops, manufactures and distributes OTC and generic prescription
(Rx) pharmaceuticals, infant formulas, nutritional products, active
pharmaceutical ingredients (API) and pharmaceutical and medical
diagnostic products. The Company is the world’s largest store brand
manufacturer of OTC pharmaceutical products and infant formulas.
The Company’s primary markets and locations of manufacturing and
logistics operations are the United States, Israel, Mexico, the
United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbor created thereby. These statements relate to future
events or the Company’s future financial performance and involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or
achievements of the Company or its industry to be materially
different from those expressed or implied by any forward-looking
statements. In some cases, forward-looking statements can be
identified by terminology such as “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “potential” or other comparable terminology.
The Company has based these forward-looking statements on its
current expectations, assumptions, estimates and projections.
While the Company believes these expectations,